We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us

Download Mobile App

AI-Based Image Analysis Software Profiles Cancer Biomarkers in Real Time

By LabMedica International staff writers
Posted on 27 Mar 2023
Print article
Image: New research has opened a path for fast and accurate cancer diagnosis (Photo courtesy of Imagene)
Image: New research has opened a path for fast and accurate cancer diagnosis (Photo courtesy of Imagene)

Lung cancer is the most widespread type of cancer worldwide, resulting in approximately 1.76 million fatalities annually. Non-small cell lung cancer (NSCLC) accounts for 85% of all lung cancer diagnoses and is typically identified at advanced stages. Due to the late detection of the disease, statistics show that 10-20% of NSCLC patients succumb within 1-3 months of diagnosis. Improving patient care and making targeted therapeutic decisions necessitates the identification of gene alterations. However, only 28% of cancer patients currently undergo a comprehensive analysis of all nine actionable cancer biomarkers, and up to 64% of lung cancer patients do not receive the best available treatment, primarily due to inadequate testing for biomarkers to determine the mutation's nature. Furthermore, in numerous instances, such as with NGS, sensitivity is significantly lower than expected, and interpretability is poor due to the requirement for highly trained specialists who understand what they are examining.

An innovative AI-based system from Imagene (Tel Aviv, Israel) can detect cancer biomarkers in real-time, potentially expediting the administration of treatment. Imagene's cutting-edge system utilizes a biopsy image, generating a biomarker report ready for diagnosis within minutes, precisely identifying the specific cancer mutation present in the biopsy. Currently, the time between biopsy and the initiation of treatment, during which cancer nature is evaluated, typically lasts for several weeks, frequently extending beyond a month. As this waiting period is too long for many patients, Imagene's technology has the potential to significantly reduce it, resulting in patients receiving diagnoses and treatment recommendations on the same day.

Detecting cancer mutations in patients and locations of diverse types is achievable with the aid of AI since cancer patterns tend to repeat themselves. Imagene combines self-supervised learning and other AI techniques, utilizing unlabeled data to enhance results, as well as proprietary processing of prepared data to analyze images. Imagene is presently collaborating with 28 diverse biomarkers across eight organs, demonstrating that their technology is standardized and yields accurate results, aiding in clinical decision-making. Currently, the technology is undergoing clinical research and will soon be commercialized while adhering to regulatory requirements. Ultimately, the technology is expected to be tissue-agnostic.

Related Links:

Platinum Member
Flu SARS-CoV-2 Combo Test
OSOM® Flu SARS-CoV-2 Combo Test
Magnetic Bead Separation Modules
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Automatic Nucleic Acid Extractor
GeneRotex 24

Print article


Clinical Chemistry

view channel
Image: The new ADLM guidance will help healthcare professionals navigate respiratory virus testing in a post-COVID world (Photo courtesy of 123RF)

New ADLM Guidance Provides Expert Recommendations on Clinical Testing For Respiratory Viral Infections

Respiratory tract infections, predominantly caused by viral pathogens, are a common reason for healthcare visits. Accurate and swift diagnosis of these infections is essential for optimal patient management.... Read more

Molecular Diagnostics

view channel
Image: The HelioLiver Dx test has met the coprimary and secondary study endpoints in the CLiMB trial (Photo courtesy of Helio Genomics)

Blood-Based Test Outperforms Ultrasound in Early Liver Cancer Detection

Patients with liver cirrhosis and chronic hepatitis B are at a higher risk for developing hepatocellular carcinoma (HCC), the most prevalent type of liver cancer. The American Association for the Study... Read more


view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more


view channel
Image: The POC PCR test shortens time for STI test results (Photo courtesy of Visby Medical)

POC STI Test Shortens Time from ED Arrival to Test Results

In a 2024 sexually transmitted infections (STIs) surveillance report by the World Health Organization (WHO), over 2.5 million cases were recorded, alongside a rise in the inappropriate use of antibiotics... Read more


view channel
Image: For 46 years, Roche and Hitachi have collaborated to deliver innovative diagnostic solutions (Photo courtesy of Roche)

Roche and Hitachi High-Tech Extend 46-Year Partnership for Breakthroughs in Diagnostic Testing

Roche (Basel, Switzerland) and Hitachi High-Tech (Tokyo, Japan) have renewed their collaboration agreement, committing to a further 10 years of partnership. This extension brings together their long-standing... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.